Jose M. Morales

Jose M. Morales is presented as a Madrid-based nephrologist, author, and volume editor whose work gives the book its central clinical architecture. His decisive significance lies in linking Hepatitis C to the full course of renal care: diagnosis of active infection, assessment of liver injury, management during Hemodialysis, surveillance on the kidney transplant waiting list, and the choice between kidney-alone and combined liver-kidney transplantation. He appears not as a fictional protagonist but as the medical authority and editorial presence through whom a dispersed field of evidence is assembled into a coherent account of risk, treatment, and transplant possibility.

Identity and Institutional Position

Jose M. Morales is identified as the volume editor of Disease, Hemodialysis and Transplantation in Contributions to Nephrology, volume 176. The volume lists him in Madrid and associates him with the Nephrology Department of Hospital 12 de Octubre and the Instituto de Investigación Hospital 12 de Octubre. His institutional identity is therefore inseparable from the book’s practical orientation: he writes from within nephrology while addressing a disease whose consequences extend beyond the kidney into the liver, circulation, immune system, and transplant program.

His editorial role is collective rather than solitary. Claudio Ronco is named as series editor, while Beatriz Domínguez-Gil is listed among the co-editors. Morales nevertheless occupies the book’s most recurrent position. He contributes to the preface, authors the chapter on Hepatitis C and renal disease, coauthors the chapter on Kidney Transplantation in the Patient with Hepatitis C Virus Infection, and appears again in the chapter on Renal Transplantation from Donors with a Positive Serology for Hepatitis C. His name also closes the subject index and returns in the author and institutional listings, making him both a contributor to individual arguments and a visible organizing presence across the volume.

Scope of His Clinical Argument

Morales’s principal subject is not Hepatitis C as an isolated hepatic disease, but Hepatitis C as a condition that changes the meaning of renal failure and its treatment. The book identifies HCV infection as a major worldwide health problem and describes it as the main cause of chronic liver disease in kidney transplant recipients. Within this framework, Morales’s chapters follow the patient across institutional thresholds: laboratory confirmation, liver staging, dialysis, waiting-list review, transplantation, immunosuppression, and post-transplant complications.

A key part of this approach is the distinction between exposure and active disease. The book explains that anti-HCV antibodies are detected by third-generation ELISA assays, whereas active infection is established by finding HCV RNA in serum through sensitive molecular testing. Chronic infection requires both anti-HCV positivity and HCV RNA positivity for more than six months. Morales’s clinical framework consequently resists treating a positive antibody result as a complete diagnosis. It asks whether infection is active, whether liver damage is present, and whether extrahepatic disease such as cryoglobulinemia-associated vasculitis or membranoproliferative glomerulonephritis changes the treatment decision.

The assessment of liver injury is equally central. Active chronic infection requires evaluation of hepatic and extrahepatic impact, with liver stage and grade assessed through liver biopsy or noninvasive methods such as biochemical scores and FibroScan elastometry. Yet the transplant-focused material gives liver biopsy a particularly authoritative status. In HCV-infected kidney transplant candidates, the KDIGO Workgroup recommends percutaneous liver biopsy because available noninvasive tests do not yet provide the accuracy and reliability of biopsy. Morales’s contribution thus places the candidate within a graded medical system in which antibody status, RNA status, fibrosis stage, cirrhosis, and clinical compensation determine access to different transplant pathways.

Waiting List, Treatment, and Eligibility

For Morales, the kidney transplant waiting list is not a passive queue. It is a continuing clinical surveillance system. Candidates who have not previously been tested should undergo anti-HCV screening with confirmation by nucleic acid testing in low-prevalence regions, or direct nucleic acid testing in high-prevalence settings. A patient with positive NAT should be placed on hold status and referred to a hepatologist for evaluation and possible treatment. The waiting list therefore becomes a site where infection is classified, eligibility is temporarily interrupted, and future treatment is negotiated.

The long duration of waiting makes this surveillance consequential. In some areas of the United States, deceased-donor waiting times approach five to seven years. During that interval, a patient’s liver disease may progress even while renal transplantation remains the intended treatment. Follow-up biopsy data illustrate the danger: among 13 wait-listed patients who underwent repeat biopsy, 8, or 62 percent, showed worsening liver histology. By contrast, only 7 of 31, or 23 percent, of follow-up biopsies obtained after transplantation showed interval worsening. Morales’s evidence presents transplantation as more than renal replacement; for appropriately selected patients, it may also alter the tempo of liver disease.

Treatment before transplantation is preferred whenever feasible because post-transplant interferon carries an increased risk of renal allograft rejection. The book also notes that sustained virological response before transplantation is usually durable after immunosuppression begins, although its effect on later liver-injury progression remains less certain. Pretransplant viral clearance may reduce the risk of post-transplant diabetes and immune complex-mediated glomerular disease, but the evidence is not presented as definitive. Treatment is difficult: interferon toxicity can produce flu-like symptoms, anemia, neutropenia, depression, and anxiety; dose reduction occurs in 35–42 percent of treated patients, and approximately 30 percent discontinue therapy.

Morales’s position is therefore pragmatic rather than absolutist. Some patients with end-stage renal disease and active HCV infection will not be treated because therapy is prolonged, expensive, poorly tolerated, unavailable, refused, or unsuccessful. Yet a positive HCV RNA result should not automatically remove them from the prospect of transplantation, since their expected course may still be more favorable with a kidney transplant than with continued dialysis. The clinical problem becomes one of individualized timing: clear the virus before transplantation when possible, but do not allow an imperfect treatment option to turn transplant candidacy into permanent exclusion.

Kidney Transplantation and Scarce Organs

Morales also addresses the allocation problem created by HCV-positive donor kidneys. Organ transplantation benefits roughly 100,000 people worldwide each year, but supply remains far below demand. At the end of 2009, the European Union had about 63,000 people on organ waiting lists while only 28,000 transplant procedures were performed that year; in the United States, nearly 111,000 people were registered in May 2011, against approximately 28,000 annual transplant procedures. Within this scarcity, kidneys from HCV-positive donors are treated as nonstandard-risk organs because HCV can be transmitted through transplantation.

The use of these kidneys varies sharply among centers and countries. Some centers never accept kidneys from HCV-positive donors, and some jurisdictions impose technical or legal prohibitions. Morales’s discussion challenges the assumption that discarding these organs is self-evidently safer. For HCV-positive recipients who are not candidates for, refuse, fail, or withdraw from interferon therapy, accepting an HCV-positive kidney may shorten time on the waiting list while preserving the overall benefit of transplantation over dialysis.

The disparity between supply and use is measurable. Donated HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys. Morales’s account treats this not simply as a technical transplant question but as an organizational one: when organs are not used locally, systems should facilitate their transfer to suitable recipients elsewhere. The proposed recipient is not an abstract risk category but a patient whose active infection, treatment prospects, waiting time, and expected survival must be considered together.

Editorial and Narrative Role

Morales’s repeated appearance creates a through-line across a book assembled from multiple authors, institutions, and clinical specialties. His name links Madrid to Toulouse, Philadelphia, Miami, and Barcelona; it connects nephrology departments with hepatologists, transplant programs, laboratories, registries, and guideline groups. The resulting authority is cumulative. A chapter on epidemiology and diagnosis leads into renal pathogenesis; renal disease leads into dialysis mortality and quality of life; those concerns lead to waiting-list surveillance, biopsy, antiviral treatment, rejection risk, and the controversial use of HCV-positive donor organs.

His editorial presence also holds together two scales of medical experience. At the population level, the book tracks prevalence, transmission, waiting-list size, organ shortage, and registry outcomes. At the patient level, it describes asymptomatic liver disease, fatigue, depression, impaired mental quality of life, treatment toxicity, and the possibility that a diagnosis may alter access to transplantation. HCV-related liver disease is often clinically silent in long-term dialysis, while its institutional consequences are substantial: patients are screened, staged, placed on hold, referred, rebiopsied, treated, or redirected toward simultaneous liver-kidney transplantation.

The figure that emerges is consequently less a biographical portrait than a map of medical responsibility. Morales stands at the intersection of evidence and decision: between anti-HCV antibody and HCV RNA, dialysis and transplantation, kidney-alone and combined transplantation, treatment opportunity and treatment toxicity, individual survival and organ scarcity. His work gives the volume a governing question: how can clinical systems protect patients from the progressive consequences of Hepatitis C without allowing classification, waiting-list rules, or risk-averse organ policy to make treatable patients invisible?